Robert W. Baird Reaffirms Neutral Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “neutral” rating restated by research analysts at Robert W. Baird in a research note issued on Tuesday, MarketBeat reports.

Several other brokerages have also recently weighed in on MRNS. StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Oppenheimer reaffirmed a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $16.07.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.38 on Tuesday. Marinus Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.26. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The stock has a fifty day moving average of $8.37 and a 200-day moving average of $8.37.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The company had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same quarter last year, the firm posted ($0.76) earnings per share. Sell-side analysts forecast that Marinus Pharmaceuticals will post -2.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of MRNS. FMR LLC lifted its stake in shares of Marinus Pharmaceuticals by 1,887.9% in the 1st quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 4,210 shares during the last quarter. BluePath Capital Management LLC purchased a new position in Marinus Pharmaceuticals during the 3rd quarter valued at about $38,000. Quantbot Technologies LP purchased a new position in Marinus Pharmaceuticals during the 1st quarter valued at about $40,000. Ameritas Investment Partners Inc. purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $45,000. Finally, Jane Street Group LLC purchased a new position in Marinus Pharmaceuticals during the 4th quarter valued at about $47,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.